Combining WEE1 inhibition with PD-L1 blockade shows promise in SCLC models
Blocking the tyrosine kinase cell-cycle progression regulator WEE1 may help to reinstate tumour immunogenicity and potentiate the effects of immune checkpoint inhibitors
Will finding the optimal dosing regimen be the key to unlocking the potential of ATR inhibitors?
Novel scheduling of RP-3500 mitigates haematological toxicity and may facilitate combination therapy but tumour types most likely to respond remain to be defined
The genomic, immunological and clinical characterisation of breast cancer – a work in progress
A greater understanding of the complexity of breast cancer, in all its forms, is key to better patient selection, new target development and improved outcomes, says Prof. Fabrice André
Sitravatinib shows signals of enhancing checkpoint inhibitor efficacy in NSCLC progressing on immunotherapy
Early-phase trials suggest that sitravatinib may reboot the tumour response to PD-1 inhibitors, but confirmation of efficacy is required and strategies are needed to adjust tolerability
Exploring targeted degradation of KRAS G12C with PROTACs
Developing therapies for cancers harbouring KRAS mutations has proven difficult but PROTACs, acting via targeted protein degradation, may help combat previously undruggable proteins
Will antibody–drug conjugates be a replacement for chemotherapy in the future?
Over the last decade, much progress has been made in developing a range of antibody–drug conjugates to treat breast cancer, with the construction of bespoke agents for individual patients and exciting prospect for the future
Lesley Seymour receives the TAT Honorary Award 2022
In her keynote lecture at the ESMO Targeted Anticancer Therapies Congress 2022, Prof. Lesley Seymour stresses the importance of sharing ideas and resources between academia and industry
Is there a future for immunotherapy in sarcoma?
Continued efforts in patient selection, combination strategies and novel approaches may help to turn the tide for immunotherapeutics in sarcoma, according to Prof. Jean-Yves Blay
Patient sex and gut microbiome play a role in modulating response to immunotherapy
Research is ongoing to investigate influencing factors of immune checkpoint inhibition, encouraging a more holistic understanding of individual characteristics to improve clinical outcomes
Optimising clinical trials for greater inclusiveness
Oncologists are aiming to capitalise on lessons learned from the COVID-19 pandemic and design more inclusive clinical trials, optimise trial endpoints and make better use of real-world evidence.